Therapies such as TILs, CAR-T, and TCR cell therapies involve harvesting T cells from the patient, allowing for ex vivo expansion with or without genetic modification, and infusing these T cells back into the patient. Since the first FDA approval of CD-19-specific CAR-T therapy for B-cell acute lymphoblastic leukemia in 2017 [153], cellular therapy has changed the treatment paradigm in hematologic malignancies. Here, CD19 is linked to B-cell acute lymphoblastic leukemia.